OMAHA, NE, Aug. 14, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife" or the "Company") (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the second quarter ended June 30, 2025. Highlights for the second quarter ended June 30, 2025 include: Legacy FitLife For the second quarter ended June 30, 2025, total revenue decreased 5% to $16.1 million compared to $16.9 million during the same period last year. Online re ...

OMAHA, NE, May 15, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. (“FitLife” or the “Company”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the first quarter ended March 31, 2025. Highlights for the first quarter ended March 31, 2025 include: Total revenue was $15.9 million, 4% lower than the first quarter of 2024. Online sales were $10.6 million, representing 67% of total revenue and down 2% compared to the firs ...

Financial Data and Key Metrics Changes - For the full year 2024, total revenue increased by 22% year over year to $64.5 million, with online sales growing by 29% and representing 67% of total revenue [3] - Gross profit increased by 31%, and gross margin expanded from 40.7% to 43.6% [3] - Net income rose by 70% to $9 million, with basic EPS increasing by 66% to $0.98 and fully diluted EPS increasing by 69% to $0.91 [3] - Adjusted EBITDA for the full year increased by 39% to $14.1 million [4] - For Q4 2024, total revenue increased by 13% to $15 million, with online revenue increasing by 12% to $10.1 million [4] Business Line Data and Key Metrics Changes - Legacy Fitlife revenue for Q4 2024 was $5.3 million, with a 20% decline in wholesale revenue and a 1% decline in online revenue, totaling a 13% decline [5][6] - MRC revenue for Q4 2024 was $6.9 million, down slightly by 0.4% year over year, but gross margin increased from 40.4% to 48.7% [9][10] - MusclePharm revenue for Q4 2024 was the strongest since acquisition, with total revenue increasing by 14% sequentially, driven by a 37% increase in wholesale revenue [13][14] Market Data and Key Metrics Changes - The company expects MRC online revenue to decline by 10-13% in Q1 2025 due to tough year-over-year comparisons [11] - The first quarter of 2025 is anticipated to see a consolidated revenue decline of 4% to 6% compared to Q1 2024, primarily due to MRC's performance [18] Company Strategy and Development Direction - The company is focused on increasing promotional spending to drive sales growth, particularly for MusclePharm, while managing gross margins [14][45] - The company is actively evaluating M&A opportunities, prioritizing larger transactions while maintaining a strong balance sheet [19][55] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for Q1 2025, expecting strong performance for legacy Fitlife despite challenges in Q4 2024 [8] - The company is taking steps to mitigate tariff impacts by exploring alternative sourcing options, particularly from India [24][28] - Management noted that while there is uncertainty in the market, they are seeing an uptick in deal flow, particularly from over-leveraged companies [60] Other Important Information - The company completed a two-for-one forward stock split on February 7, 2025, with all per-share amounts adjusted retroactively [3] - The balance sheet remains strong, with net debt at $8.6 million, equivalent to 0.6 times the company's LTM adjusted EBITDA [4][19] Q&A Session Summary Question: What is the potential tariff impact and sourcing from China? - The company does not source products from China but is assessing where manufacturers obtain ingredients, with India emerging as a promising alternative [22][24] Question: What are the dynamics affecting MRC's performance? - The decline in MRC revenue is attributed to tough year-over-year comparisons and changes in customer purchasing behavior [29][30] Question: What are the expectations for MusclePharm's ramp-up throughout the year? - The company is optimistic about MusclePharm's growth potential, particularly with new product launches and rebranding efforts [39][42] Question: Can gross margins be increased? - Gross margins could be increased by stopping promotional spending, but the focus is on growth rather than immediate margin improvement [71][73] Question: What is the company's approach to promotional expenses? - Promotional expenses are used to incentivize retailers to promote products, and the company can adjust these as needed based on performance [45][51]

Financial Data and Key Metrics Changes - For the full year 2024, total revenue increased by 22% year over year to $64.5 million, with online sales growing by 29% and representing 67% of total revenue [3][4] - Gross profit increased by 31%, and gross margin expanded from 40.7% to 43.6% [3] - Net income rose by 70% to $9 million, with basic EPS increasing by 66% to $0.98 and fully diluted EPS increasing by 69% to $0.91 [3] - Adjusted EBITDA for the full year increased by 39% to $14.1 million [4] - For Q4 2024, total revenue increased by 13% to $15 million, with online revenue increasing by 12% to $10.1 million [4] Business Line Data and Key Metrics Changes - Legacy Fitlife revenue for Q4 2024 was $5.3 million, with a 20% decline in wholesale revenue and a 1% decline in online revenue, totaling a 13% decline [5][6] - MRC revenue for Q4 2024 was $6.9 million, down slightly by 0.4% year over year, but gross margin increased from 40.4% to 48.7% [9][10] - MusclePharm revenue for Q4 2024 was the strongest since acquisition, with total revenue increasing by 14% sequentially, driven by a 37% increase in wholesale revenue [13][14] Market Data and Key Metrics Changes - The company expects MRC online revenue to decline by 10-13% in Q1 2025 due to tough year-over-year comparisons [11] - The first quarter of 2025 is anticipated to see a consolidated revenue decline of 4% to 6% compared to the first quarter of 2024 [18] Company Strategy and Development Direction - The company is focused on transitioning to direct fulfillment for GNC franchisees after resolving a commercial dispute [8] - There is an ongoing effort to optimize the skincare brands acquired in the MRC transaction, which had unprofitable revenue [10] - The company is actively evaluating M&A opportunities, prioritizing larger transactions while maintaining a strong balance sheet [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for Q1 2025, expecting strong performance for legacy Fitlife despite challenges in wholesale [9] - The company is taking proactive steps to mitigate potential tariff impacts by sourcing ingredients from alternative suppliers [24][28] - Management noted that while there is uncertainty in the market, they are seeing an uptick in deal flow, particularly from over-leveraged companies [60] Other Important Information - The company completed a two-for-one forward stock split on February 7, 2025, with all per-share amounts adjusted retroactively [3] - The balance sheet remains strong, with net debt at $8.6 million, equivalent to 0.6 times the company's LTM adjusted EBITDA [4][19] Q&A Session Summary Question: What is the potential tariff impact and sourcing from China? - The company does not source products from China but is assessing where manufacturers obtain ingredients, with India emerging as a promising alternative [22][24] Question: What are the dynamics affecting MRC business? - The decline in MRC revenue is attributed to tough year-over-year comparisons and changes in customer purchasing behavior [29][34] Question: What are the expectations for MusclePharm's ramp-up? - The company is optimistic about MusclePharm's growth potential but cannot provide specific numbers at this time [39][42] Question: How does promotional spending affect gross margins? - Promotional spending is typical in the industry and is accounted for as a reduction in gross revenue, impacting reported gross margins [45][49] Question: What is the company's approach to M&A targets? - The company is looking for larger M&A opportunities and can leverage its strong balance sheet to finance acquisitions [56][60] Question: What were MusclePharm's peak sales and future potential? - MusclePharm's peak revenue was over $175 million, and the company aims to recover a significant portion of that in the future [63][66]